Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0O2NQ
|
|||
| Former ID |
DCL000522
|
|||
| Drug Name |
Eraxis/Vfend
|
|||
| Indication | Fungal infection [ICD-11: 1F29-1F2F; ICD-10: B35-B49; ICD-9: 110-118] | Phase 3 | [1] | |
| Company |
Pfizer
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fungal Papulacandin B resistance protein 1 (Fung FKS1) | Target Info | Inhibitor | [2], [3] |
| KEGG Pathway | Starch and sucrose metabolism | |||
| MAPK signaling pathway - yeast | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Pfizer. | |||
| REF 2 | Pfizer. Product Development Pipeline. March 31 2009. | |||
| REF 3 | Eraxis. News for Eraxis. 2008. eduDrugs. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.